Modeling of human brain diseases in experiments on rodents (brief overview)

The review summarizes the successes and difficulties in creating and using biological models of the human brain diseases, which belongs to the important issues of applied Neurobiology. The review mentions and attempts to theoretically comprehend the relative role of genotype, environmental influences and their dynamic interactions (LEARN concept). The article reviews the examples of developed genetic models of human diseases (Alzheimer's, Down syndrome, Autism, etc.). When creating models of anxiety disorders the focus is made on the difficult problem of "norm" and "pathology", as well as the importance of integrating and understanding species specific behavior of animals used as biological models of this kind.

1. A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition. Kim H., [et al.]. Disease Models & Mechanisms, 2016. Vol. 9, pp. 839–884. doi: 10.1242/dmm.025668
2. Shu W., et al. Altered ultrasonic vocalization in mice with a disruption in the Foxp2 gene. Proceedings of the National Academy of Sciences of the United States of America. 2005. Vol. 102, no. 27, pp. 9643–9648. doi: 10.1073/pnas.0503739102
3. McFarlane H.G., et al. Autism-like behavioral phenotypes in BTBR T+tf/J mice. Genes, Brain and Behavior, 2007. Vol. 7, no. 2, pp. 152–163. doi: 10.1111/j.1601-183X.2007.00330.x
4. Hogg S., et al. Behavioral profiles of genetically selected aggressive and nonaggressive male wild house mice in two anxiety tests. Behavior Genetics, 2000. Vol. 30, no. 6, pp. 439–446. doi: 10.1023/A:1010246717180
5. Belzung C., Le Guisquet A.M., Crestani F. Flumazenil induces benzodiazepine partial agonist-like effects in BALB/c but not C57BL/6 mice. Psychopharmacology, 2000. Vol. 148, no. 1, pp. 24–32. doi: 10.1007/s002130050021
6. Bilkei-Gorzo A. Genetic mouse models of brain ageing and Alzheimer's disease. Pharmacol Ther, 2014. Vol. 142, no. 2, pp. 244–257. doi: 10.1016/j.pharmthera.2013.12.009
7. Blanchard R.J., Blanchard D.C. Bringing natural behaviors into the laboratory: a tribute to Paul MacLean. Physiology & Behavior, 2003. Vol. 79, no. 3, pp. 515–524. doi: 10.1016/S0031-9384(03)00157-4
8. Bouwknecht J.A., Paylor R. Behavioral and physiological mouse assays for anxiety: a survey in nine mouse strains. Behavioural Brain Research, 2002. Vol. 136, no. 2, pp. 489–501. doi: 10.1016/S0166-4328(02)00200-0
9. Bouwknecht J.A., Paylor R. Pitfalls in the interpretation of genetic and pharmacological effects on anxiety-like behaviour in rodents. Behavioural Pharmacology, 2008. Vol. 19, no. 5–6, pp. 385–402. doi: 10.1097/FBP.0b013e32830c3658
10. Chadman K.K. Fluoxetine but not risperidone increases sociability in the BTBR mouse model Pharmacology. Pharmacology Biochemistry and Behavior, 2011. Vol. 97, no. 3, pp. 586–594. doi: 10.1016/j.pbb.2010.09.012
11. Ohl F., et al. Cognitive performance in rats differing in their inborn anxiety. Behavioral Neuroscience, 2002. Vol. 116, no. 3, P. 464–471. doi: 10.1037/0735-7044.116.3.464
12. Brenndörfer J., et al. Connecting anxiety and genomic copy number variation: a genome-wide analysis in CD-1 Mice. PLoS One, 2015. Vol. 10, no. 5. doi: 10.1371/journal.pone.0128465
13. Crawley J.N., Davis L.G. Baseline exploratory activity predicts anxiolytic responsiveness to diazepam in five mouse strains. Brain Research Bulletin, 1982. Vol. 8, no. 6, pp. 609–612. doi: 10.1016/0361-9230(82)90087-9
14. Wahlsten D., et al. Different data from different labs: lessons from studies of gene-environment interaction. Journal of neurobiology, 2003. Vol. 54, no. 1, pp. 283–311. doi: 10.1002/neu.10173
15. Hager T., et al. Display of individuality in avoidance behavior and risk assessment of inbred mice. Frontiers in Behavioral Neuroscience, 2014. Vol. 8, pp. 1–12. doi: 10.3389/fnbeh.2014.00314
16. Simmons R.K., et al. DNA methylation in the developing hippocampus and amygdala of anxiety-prone versus risk-taking rats. Developmental neuroscience, 2012. Vol. 34, no. 1, pp. 58–67. doi: 10.1159/000336641
17. Enard W. FOXP2 and the role of cortico-basal ganglia circuits in speech and language evolution. Current Opinion in Neurobiology, 2011. Vol. 21, no. 3, pp. 415–424. doi: 10.1016/j.conb.2011.04.008
18. Ennaceur A., Chazot P.L. Preclinical animal anxiety research – flaws and prejudices. Pharmacology Research & Perspectives, 2016. Vol. 4, no. 2, pp. 1–37. doi: 10.1002/prp2.223
19. Ennaceur A. Tests of unconditioned anxiety – pitfalls and disappointments. Physiology & Behavior, 2014. Vol. 135, pp. 55–71 doi: 10.1016/j.physbeh.2014.05.032
20. Mitchell K.J., et al. Following the genes: a framework for animal modeling of psychiatric disorders. BMC Biology, 2011. Vol. 9, no. 76, pp. 1–13. doi: 10.1186/1741-7007-9-76
21. McBrayer Z.L., et al. Forebrain-specific loss of BMPRII in mice reduces anxiety and increases object exploration. PLoS One, 2015. Vol. 10, no. 10, pp. 1–19. doi: 10.1371/journal.pone.0139860
22. Guillot P.V., Chapouthier G. Intermale aggression and dark/light preference in ten inbred mouse strains. Behavioural Brain Research, 1996. Vol. 77, no. 1–2, pp. 211–213. doi: 10.1016/0166-4328(95)00163-8
23. Sakurai T., et al. Haploinsufficiency of Gtf2i, a gene deleted in Williams Syndrome, leads to increases in social interactions. Autism Research, 2011. Vol. 4, pp. 28–39. doi: 10.1002/aur.169
24. D'Amico D., et al. Infralimbic Neurotrophin-3 Infusion Rescues Fear Extinction Impairment in a Mouse Model of Pathological Fear. Neuropsychopharmacology, 2017. Vol. 42, no. 2, pp. 462–472. doi: 10.1038/npp.2016.154
25. Insel T.R. From animal models to model animals. Biol Psychiatry, 2007. Vol. 62, no. 12, pp. 1337–1339. doi: 10.1016/j.biopsych.2007.10.001
26. Ramos A., et al. Integrating the open field, elevated plus maze and light/dark box to assess different types of emotional behaviors in one single trial. Behavioural Brain Research, 2008. Vol. 193, no. 2, pp. 277–288. doi: 10.1016/j.bbr.2008.06.007
27. Isaksen T.J., Lykke-Hartmann K. Insights into the Pathology of the α2-Na(+)/K(+)-ATPase in Neurological Disorders; Lessons from Animal Models. Frontiers in physiology, 2016. Vol. 7, no. 161, pp. 44–52. doi: 10.3389/fphys.2016.00161
28. Jacobson L.H., Cryan J.F. Genetic approaches to modeling anxiety in animals. Behavioral Neurobiology of Anxiety and Its Treatment. Springer Berlin Heidelberg. 2009. Vol. 2, pp. 161–201. doi: 10.1007/7854_2009_31
29. Lahiri D.K., Maloney B., Zawia N.H. The LEARn model: an epigenetic explanation for idiopathic neurobiological diseases. Molecular psychiatry, 2009. Vol. 14, pp. 992–1003. doi: 10.1038/mp.2009.82
30. Lalonde R., Strazielle C. Relations between open-field, elevated plus-maze, and emergence tests in C57BL/6J and BALB/c mice injected with GABA- and 5HT-anxiolytic agents. Fundamental & clinical pharmacology, 2010. Vol. 24, no. 3, pp. 365–376. doi: 10.1111/j.1472-8206.2009.00772.x
31. Landgraf R., Wigger A. High vs low anxiety-related behavior rats: an animal model of extremes in trait anxiety. Behavior Genetics, 2002. Vol. 32, no. 5, pp. 301–314. doi: 10.1023/A:1020258104318
32. Voikar V., et al. Long-term individual housing in C57BL/6J and DBA/2 mice: assessment of behavioral consequences. Genes, Brain and Behavior, 2005. Vol. 4, no. 4, pp. 240–252. doi: 10.1111/j.1601-183X.2004.00106.x
33. Löscher W. Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies. Epilepsy Research, 2016. Vol. 126, pp. 157–184. doi: 10.1016/j.eplepsyres.2016.05.016.
34. Babineau B.A., et al. Mainstreaming Mice. Neuropsychopharmacology, 2012. Vol. 37, no. 1, pp. 300–301; doi: 10.1038/npp.2011.168
35. Martínez-Cué C., Delatour B., Potier M.C. Treating enhanced GABAergic inhibition in Down syndrome: use of GABA α5-selective inverse agonists. Neuroscience & Biobehavioral Reviews, 2014. Vol. 46, no. 2, pp. 218–227. doi: 10.1016/j.neubiorev.2013.12.008
36. Matzel L.D., Kolata S. Selective attention, working memory, and animal intelligence. Neuroscience & Biobehavioral Reviews, 2010. Vol. 34, no. 1, pp. 23–30 doi: 10.1016/j.neubiorev.2009.07.002
37. McEwen B.S., Gray J.D., Nasca C. 60 years of neuroendocrinology: Redefining neuroendocrinology: stress, sex and cognitive and emotional regulation.Journal of endocrinology, 2015. Vol. 226, no. 2, pp. T67-T83. doi: 10.1530/JOE-15-0121
38. McKinney P. Teaching model for rhinoplasty. Plastic & Reconstructive Surgery, 1984. Vol. 74, no. 6, pp. 846–846.
39. Mo C., Renoir T., Hannan A.J. What's wrong with my mouse cage? Methodological considerations for modeling lifestyle factors and gene-environment interactions in mice. Journal of Neuroscience Methods, 2016. Vol. 265, pp. 99–108. doi: 10.1016/j.jneumeth.2015.08.008
40. Möhler H. Cognitive enhancement by pharmacological and behavioral interventions: the murine Down syndrome model. Biochemical Pharmacology, 2012. Vol. 84, no. 8, pp. 994–999. doi: 10.1016/j.bcp.2012.06.028
41. Kanari K., et al. Multidimensional structure of anxiety-related behavior in early-weaned rats. Behavioural Brain Research, 2005. Vol. 156, no. 1, pp. 45–52. doi: 10.1016/j.bbr.2004.05.008
42. Ditzen C., et al. Protein Biomarkers in a Mouse Model of Extremes in Trait Anxiety [Electronic resource]. Molecular & Cellular Proteomics. 2006. Vol. 5, no. 10, pp. 1914–1920. URL: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.575.2694&rep=rep1&type=pdf (Accessed 26.12.2016).
43. Qureshi I.A., Mehler M.F. Epigenetics and therapeutic targets mediating neuroprotection. Brain Research, 2015. Vol. 1628, Part B, pp. 265–272 doi: 10.1016/j.brainres.2015.07.034
44. Potier M.C., et al. Reducing GABAergicinhibition restores cognitive functions in a mouse model of Down syndrome. CNS Neurol Disord Drug Targets, 2014. Vol. 13, no. 1, pp. 8–15. doi: 10.2174/18715273113126660185
45. Laviola G., et al. Risk-taking behavior in adolescent mice: psychobiological determinants and early epigenetic influence. Neuroscience and Biobehavioral Reviews, 2003. Vol. 27, no. 1–2, pp. 19–31. doi: 10.1016/S0149-7634(03)00006-X
46. Rodgers R.J. Animal models of 'anxiety': where next? [Electronic resource] Behavioural pharmacology, 1997. Vol. 8, no. 6–7, pp. 477–496. URL: http://journals.lww.com/behaviouralpharm/Abstract/1997/11000/Animal_models_of__anxiety___where_next_.3.aspx (Accessed 26.12.2016).
47. Scattoni M.L., Ricceri L., Crawley J.N. Unusual repertoire of vocalizations in adult BTBR T+tf/J mice during three types of social encounters. Genes, Brain and Behavior, 2011. Vol. 10, no. 1, pp. 44–56. doi: 10.1111/j.1601-183X.2010.00623.x
48. D. Colas, et al. Short-term treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained pro-cognitive benefit in a mouse model of Down's syndrome. British journal of pharmacology, 2013. Vol. 169, no. 5, pp. 963–973. doi: 10.1111/bph.12169
49. McEwen B.S., et al. The brain on stress: Insight from studies using the Visible Burrow System. Physiology & Behavior, 2015. Vol. 146, pp. 47–56. doi: 10.1016/j.physbeh.2015.04.015
50. Poletaeva I.I., et al. The Krushinsky-Molodkina rat strain: The study of audiogenic epilepsy for 65years. Epilepsy & Behavior, 2015. doi: 10.1016/j.yebeh.2015.04.072
51. Vorhees C.V., Makris S.L. Assessment of learning, memory, and attention in developmental neurotoxicity regulatory studies: synthesis, commentary, and recommendations. Neurotoxicology and Teratology, 2015. Vol. 52, Part A, pp. 109–115. doi: 10.1016/j.ntt.2015.10.004
52. Yee B.K., Singer P. A conceptual and practical guide to the behavioural evaluation of animal models of the symptomatology and therapy of schizophrenia. Cell and Tissue Research, 2013. Vol. 354, no. 1, pp. 221–246. doi: 10.1007/s00441-013-1611-0